Intraperitoneal injection of magnetic Fe3O4-nanoparticle induces hepatic and renal tissue injury via oxidative stress in mice

Ma, Ping; Luo, Qing; Chen, Jiaoe; Ye, Gan; Du, Juan; Ding, Shuzhe; Xi, Zhuge; Xu, Yang

doi:10.2147/ijn.s34349

Cited by 52 publications

(20 citation statements)

References 42 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When under an AMF, MIONs generated enough heat to induce cell death within tumors. A separate mouse study determined that up to 5 mg/kg of MIONs can be safely delivered intraperitoneally although at higher levels, signs of oxidative damage were detected within the hepatic and renal tissues (Ma et al, 2012 ). Furthermore, monocyte/macrophage-like cells with a propensity to migrate into tumors, can be loaded with MIONs externally and injected intraperitoneally, after which the cells will direct MIONs for magnetic hyperthermia (Basel et al, 2012 ).…”

Section: Mode Of Deliverymentioning

confidence: 99%

Biologically Targeted Magnetic Hyperthermia: Potential and Limitations

et al. 2018

View full text Add to dashboard Cite

Hyperthermia, the mild elevation of temperature to 40–43°C, can induce cancer cell death and enhance the effects of radiotherapy and chemotherapy. However, achievement of its full potential as a clinically relevant treatment modality has been restricted by its inability to effectively and preferentially heat malignant cells. The limited spatial resolution may be circumvented by the intravenous administration of cancer-targeting magnetic nanoparticles that accumulate in the tumor, followed by the application of an alternating magnetic field to raise the temperature of the nanoparticles located in the tumor tissue. This targeted approach enables preferential heating of malignant cancer cells whilst sparing the surrounding normal tissue, potentially improving the effectiveness and safety of hyperthermia. Despite promising results in preclinical studies, there are numerous challenges that must be addressed before this technique can progress to the clinic. This review discusses these challenges and highlights the current understanding of targeted magnetic hyperthermia.

show abstract

Section: Mode Of Deliverymentioning

confidence: 99%

Biologically Targeted Magnetic Hyperthermia: Potential and Limitations

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Over the last two decades there has been an increase in the use of magnetic particles and magnetic microspheres including iron oxide nanoparticles (IONPs) and superparamagnetic iron oxide nanoparticles (SPIONs) for bio-medical applications such as imaging, diagnostics, therapies and theranostics, but their suitability for these applications ultimately depends on their biodistribution and toxicity profiles [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20]. The two main administration routes for IONPs into the body are intravenous (IV) injection and intraperitoneal (IP) injection.…”

Section: Introductionmentioning

confidence: 99%

“…The two main administration routes for IONPs into the body are intravenous (IV) injection and intraperitoneal (IP) injection. While IP injection offers a longer plasma half-life of particles since it takes longer for the particles to reach circulation, a limited number of studies have been reported, and IV injection remains the most common clinical administration route [8,19,21,22,23,24,25,26]. Biodistribution studies have found that IONPs are localized primarily to the liver and spleen for clearance via mononuclear phagocytes [3,4,7,10,11,13,27,28,29,30,31].…”

Section: Introductionmentioning

confidence: 99%

“…Several biodistribution studies performed with Feraheme™ (IONPs surrounded by a carbohydrate coat) demonstrated retention times longer than 7 days in mice, with IONPs still detectable in the liver and spleen of the treated mice at this point in time [10,12,13,34]. Ma and co-workers [19] reported that for IP injection of magnetic 35 nm diameter positively charged Fe 3 O 4 nanoparticles from Sigma-Aldrich (Castle Hill, Australia), the safe upper limit was 5 mg/kg administered daily to mice for one week. This equates to a total injection of 35 mg/kg body weight per mouse.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Biodistribution and Clearance of Stable Superparamagnetic Maghemite Iron Oxide Nanoparticles in Mice Following Intraperitoneal Administration

Pham

Colvin

Phạm

et al. 2018

IJMS

View full text Add to dashboard Cite

Nanomedicine is an emerging field with great potential in disease theranostics. We generated sterically stabilized superparamagnetic iron oxide nanoparticles (s-SPIONs) with average core diameters of 10 and 25 nm and determined the in vivo biodistribution and clearance profiles. Healthy nude mice underwent an intraperitoneal injection of these s-SPIONs at a dose of 90 mg Fe/kg body weight. Tissue iron biodistribution was monitored by atomic absorption spectroscopy and Prussian blue staining. Histopathological examination was performed to assess tissue toxicity. The 10 nm s-SPIONs resulted in higher tissue-iron levels, whereas the 25 nm s-SPIONs peaked earlier and cleared faster. Increased iron levels were detected in all organs and body fluids tested except for the brain, with notable increases in the liver, spleen, and the omentum. The tissue-iron returned to control or near control levels within 7 days post-injection, except in the omentum, which had the largest and most variable accumulation of s-SPIONs. No obvious tissue changes were noted although an influx of macrophages was observed in several tissues suggesting their involvement in s-SPION sequestration and clearance. These results demonstrate that the s-SPIONs do not degrade or aggregate in vivo and intraperitoneal administration is well tolerated, with a broad and transient biodistribution. In an ovarian tumor model, s-SPIONs were shown to accumulate in the tumors, highlighting their potential use as a chemotherapy delivery agent.

show abstract

“…В ис-следовании эффекта частичного окисления («старе-ние») и модификации поверхности наночастиц Fe 0 потенциальную нейротоксичность в условиях in vitro на культурах клеток микроглии (BV2) и нейронов (N27) грызунов установлено, что частичное или по-лное окисление наночастиц Fe 0 приводит к пониже-нию их окислительно-восстановительной активнос-ти, вероятно снижает токсичность относительно клеточных культур млекопитающих [4]. Установле-но, что наночастицы Fe 3 O 4 размером 35 нм при семи-кратном внутрибрюшинном введении в дозе 40 мг/кг мышам вызывают нарушения антиоксидантно-про-оксидантного равновесия в тканях печени и почек, в пользу чего свидетельствует увеличение уровня мар-керов оксидативного стресса [13]. Таким образом, данные об образовании свободных радикалов путем окисления металлического железа (Fe 0 ) ставят во-прос о возможности участия в механизмах действия НЧЖ такого радикала, как оксида азота.…”

Section: Discussionunclassified